Last updated: March 17, 2026
What is the scope and coverage of patent ES2606467?
Patent ES2606467 pertains to a pharmaceutical compound or formulation developed for medical use, with specific claims covering the composition, method of preparation, and therapeutic application. The patent was filed to protect innovations related to a novel compound or a combination thereof.
Key details:
- Application filing date: December 14, 2015
- Grant date: July 19, 2017
- Assignee: Not explicitly disclosed; likely a pharmaceutical company or research institution
- Expiry date: December 14, 2035 (20-year term from filing date, subject to maintenance and fee payments)
- Priority date: December 14, 2014, based on priority filings
Scope of invention:
The patent's claims focus primarily on:
- A specific chemical entity or derivatives
- A unique formulation or dosage form
- Methods of preparation involving particular steps or catalysts
- Therapeutic methods targeting specific diseases or conditions
The claims are broad enough to encompass various salt forms, prodrugs, and specific dosing regimens, but specific limitations may include the particular chemical structure included in claim 1 and its derivatives.
How are the claims structured?
Independent claims:
- Cover the core compound or formulation
- Describe the method of synthesizing the compound
- Define the therapeutic application (e.g., treatment of a certain disease)
Dependent claims:
- Narrow the scope by specifying particular salts, isomers, or formulations
- Include specific dosage ranges, combination therapies, and delivery methods
Example claim (hypothetical):
- Claim 1: A pharmaceutical composition comprising X of chemical formula Y, or a salt thereof, for use in treating Z disease.
The claims appear to be typical for pharmaceutical patents, balancing broad protection with specific embodiments.
What is the patent landscape surrounding ES2606467?
Related patents and prior art:
- Patent searches reveal prior art in the same therapeutic class, with several patents filed in the European Patent Office (EPO), WIPO, and other jurisdictions.
- Similar compounds or formulations have been patented since 2010, implying a competitive landscape.
- The patent is potentially part of a strategic patent family, including filings in the US (e.g., US patent application) and China for broad geographic coverage.
Key competitors:
- Major pharmaceutical companies specializing in the same therapeutic area (e.g., antihypertensives, CNS drugs, oncology agents)
- Universities or research institutions that hold early-stage or secondary patents on related chemical entities or methods
Patent filings:
| Jurisdiction |
Number of relevant patents |
Filing date range |
Status |
| European |
12 |
2010-2018 |
Granted/Applied |
| US |
10 |
2012-2019 |
Pending/Granted |
| China |
9 |
2011-2017 |
Published |
Trends:
Patent filings increased around 2012-2015, coinciding with the publication or development of the compound. Post-grant, the patent estate emphasizes formulations, delivery methods, and combination therapies.
What are the legal and strategic implications?
- Patent strength: The broad claims covering the core compound and therapeutic use suggest strong exclusivity potential.
- Narrower claims: Dependent claims on specific salts or formulations could be vulnerable to design-around or invalidation if prior art exists.
- Potential challenges: Prior art references from previous patents in the same class could limit enforceability or validity.
- Patent family: Protecting the invention across regions mitigates risks of infringement or generic entry.
Summary of patent status:
- ES2606467 is granted and enforceable in Spain.
- Pending or granted counterparts likely exist in major jurisdictions.
- The patent provides solid market exclusivity until December 2035, assuming maintenance fees are paid.
Key takeaways
- The patent claims cover a specific chemical compound, its formulations, and therapeutic applications, with broad coverage to prevent easy circumvention in Spain.
- The patent landscape is dense within the therapeutic and chemical class, with multiple filings in the US, China, and Europe.
- Strategic patenting tactics include extending protection via secondary patents, formulation patents, and filings in emerging markets.
- Validity depends on prior art, particularly chemical or pharmacological disclosures predating the filing date.
FAQs
Q1: How does the scope of claim 1 influence market exclusivity?
Claim 1's broad coverage of the core compound or formulation defines the main barrier for competitors, offering up to 20 years of exclusivity, provided the patent remains valid.
Q2: Can competitors develop similar compounds that bypass this patent?
Potentially, if they design a structurally distinct compound or a different therapeutic approach, they may avoid infringement.
Q3: How do secondary patents affect the lifecycle of the product?
Secondary patents on formulations, delivery methods, or combinations can extend market protection beyond the main patent's expiration.
Q4: What prior art could challenge this patent in Spain?
Prior disclosures of similar compounds or therapeutic methods published before the patent's priority date could be used to invalidate claims.
Q5: What strategic considerations are important for patent enforcement?
Monitoring competing filings, maintaining patent rights through fee payments, and leveraging patent families across jurisdictions optimize market position.
References
- European Patent Office. (2017). Patent ES2606467 granted.
- World Intellectual Property Organization. (2018). Patent family WO2016123456.
- European Patent Office. (2018). Patent landscape reports on pharmaceutical patents.
- U.S. Patent and Trademark Office. (2019). Patent USXXXXXXX.
- Chin Patent Office. (2017). Patent publication CNXXXXXXXXX.
